Konstantopoulos K, Thomas SN (2009). “Cancer cells in transit: the vascular interactions of tumor cells”. Annual Review of Biomedical Engineering. 11: 177–202. doi:10.1146/annurev-bioeng-061008-124949. PMID19413512.
Thomas SN, Tong Z, Stebe KJ, Konstantopoulos K (2009). “Identification, characterization and utilization of tumor cell selectin ligands in the design of colon cancer diagnostics”. Biorheology. 46 (3): 207–25. doi:10.3233/BIR-2009-0534. PMID19581728.
Duffy MJ, van Dalen A, Haglund C, Hansson L, Klapdor R, Lamerz R, Nilsson O, Sturgeon C, Topolcan O (tháng 4 năm 2003). “Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines”. European Journal of Cancer. 39 (6): 718–27. doi:10.1016/S0959-8049(02)00811-0. PMID12651195.
Ballesta AM, Molina R, Filella X, Jo J, Giménez N (1995). “Carcinoembryonic antigen in staging and follow-up of patients with solid tumors”. Tumour Biology. 16 (1): 32–41. doi:10.1159/000217926. PMID7863220.
Maestranzi S, Przemioslo R, Mitchell H, Sherwood RA (tháng 1 năm 1998). “The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA”. Annals of Clinical Biochemistry. 35 (Pt 1) (1): 99–103. doi:10.1177/000456329803500113. PMID9463746.
Goldstein MJ, Mitchell EP (2005). “Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer”. Cancer Investigation. 23 (4): 338–51. doi:10.1081/CNV-58878. PMID16100946.
Konstantopoulos K, Thomas SN (2009). “Cancer cells in transit: the vascular interactions of tumor cells”. Annual Review of Biomedical Engineering. 11: 177–202. doi:10.1146/annurev-bioeng-061008-124949. PMID19413512.
Thomas SN, Tong Z, Stebe KJ, Konstantopoulos K (2009). “Identification, characterization and utilization of tumor cell selectin ligands in the design of colon cancer diagnostics”. Biorheology. 46 (3): 207–25. doi:10.3233/BIR-2009-0534. PMID19581728.
Duffy MJ, van Dalen A, Haglund C, Hansson L, Klapdor R, Lamerz R, Nilsson O, Sturgeon C, Topolcan O (tháng 4 năm 2003). “Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines”. European Journal of Cancer. 39 (6): 718–27. doi:10.1016/S0959-8049(02)00811-0. PMID12651195.
Ballesta AM, Molina R, Filella X, Jo J, Giménez N (1995). “Carcinoembryonic antigen in staging and follow-up of patients with solid tumors”. Tumour Biology. 16 (1): 32–41. doi:10.1159/000217926. PMID7863220.
Maestranzi S, Przemioslo R, Mitchell H, Sherwood RA (tháng 1 năm 1998). “The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA”. Annals of Clinical Biochemistry. 35 (Pt 1) (1): 99–103. doi:10.1177/000456329803500113. PMID9463746.
Sajid KM, Parveen R, Durr-e-Sabih, Chaouachi K, Naeem A, Mahmood R, Shamim R (tháng 12 năm 2007). “Carcinoembryonic antigen (CEA) levels in hookah smokers, cigarette smokers and non-smokers”. JPMA. The Journal of the Pakistan Medical Association. 57 (12): 595–9. PMID18173042.
Goldstein MJ, Mitchell EP (2005). “Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer”. Cancer Investigation. 23 (4): 338–51. doi:10.1081/CNV-58878. PMID16100946.
Cheng KT (2013). “99mTc-Arcitumomab”. Molecular Imaging and Contrast Agent Database (MICAD). Bethesda (MD): National Center for Biotechnology Information (US).